How much revenue does Natco Pharma make?

Natco Pharma reported 44.12 billion INR in revenue for fiscal year 2025, up 10.9% from 39.79 billion INR in fiscal year 2024. In Q2 2026 revenue was 13.63 billion INR.

What is Natco Pharma's largest business segment?

Pharmaceuticals, with 43.69 billion INR or 99% of segment revenue in fiscal year 2025. Next: Agro Chemicals (1%).

Where does Natco Pharma make most of its revenue?

United States of America: 71% of revenue by region in fiscal year 2025, followed by Rest of The World (16%).

What companies are similar to Natco Pharma?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Eris Lifesciences Limited (ERIS.NS), Alembic Pharmaceuticals Limited (APLLTD.BO), Jubilant Pharmova Limited (JUBLPHARMA.NS), Strides Pharma Science Limited (STAR.NS).

Natco Pharma Limited (NATCOPHARM.NS) Stock

About Natco Pharma Limited

NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Agrochemicals. The company offers formulations in various therapeutic areas, includin...

At a glance

Natco Pharma reported revenue of 44.12 billion INR for fiscal year 2025, up 10.9% from fiscal year 2024, and net income of 18.85 billion INR. In Q2 2026 (the quarter ended September 30, 2025) revenue was 13.63 billion INR, down 0.6% from a year before. Its largest business segment, Pharmaceuticals, brought in 99% of segment revenue in fiscal year 2025; United States of America was the largest region with 71%.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.